Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
About this item
Full title
Author / Creator
MOVe-OUT Study Group , Jayk Bernal, Angélica , Gomes da Silva, Monica M , Musungaie, Dany B , Kovalchuk, Evgeniy , Gonzalez, Antonio , Delos Reyes, Virginia , Martín-Quirós, Alejandro , Caraco, Yoseph , Williams-Diaz, Angela , Brown, Michelle L , Du, Jiejun , Pedley, Alison , Assaid, Christopher , Strizki, Julie , Grobler, Jay A , Shamsuddin, Hala H , Tipping, Robert , Wan, Hong , Paschke, Amanda , Butterton, Joan R , Johnson, Matthew G and De Anda, Carisa
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Oral outpatient treatment for Covid-19 is needed. In this phase 3, double-blind, randomized, controlled trial, molnupiravir, a small-molecule antiviral, was studied in unvaccinated patients with less than 5 days of Covid-19 illness. By day 29, hospitalization for progression of Covid-19 was lower with molnupiravir (6.8%) than with placebo (9.7%).
Alternative Titles
Full title
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Authors, Artists and Contributors
Author / Creator
Jayk Bernal, Angélica
Gomes da Silva, Monica M
Musungaie, Dany B
Kovalchuk, Evgeniy
Gonzalez, Antonio
Delos Reyes, Virginia
Martín-Quirós, Alejandro
Caraco, Yoseph
Williams-Diaz, Angela
Brown, Michelle L
Du, Jiejun
Pedley, Alison
Assaid, Christopher
Strizki, Julie
Grobler, Jay A
Shamsuddin, Hala H
Tipping, Robert
Wan, Hong
Paschke, Amanda
Butterton, Joan R
Johnson, Matthew G
De Anda, Carisa
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2611660807
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2611660807
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2116044
